Business Description
Xbrane Biopharma AB
ISIN : SE0007789409
Compare
Compare
Traded in other countries / regions
XBRANE.Sweden7XB.GermanyXBRANs.UK IPO Date
2020-07-21Description
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. Xbrane's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.28 | |||||
| Equity-to-Asset | 0.26 | |||||
| Debt-to-Equity | 1.35 | |||||
| Debt-to-EBITDA | -0.76 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -3.31 | |||||
| Beneish M-Score | 2.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 177.8 | |||||
| 3-Year EBITDA Growth Rate | 3.2 | |||||
| 3-Year EPS without NRI Growth Rate | 3.5 | |||||
| 3-Year FCF Growth Rate | -3.3 | |||||
| 3-Year Book Growth Rate | -20.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.63 | |||||
| 9-Day RSI | 34.24 | |||||
| 14-Day RSI | 38.64 | |||||
| 6-1 Month Momentum % | -86.52 | |||||
| 12-1 Month Momentum % | -97.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.41 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.2 | |||||
| Days Inventory | 157.82 | |||||
| Days Sales Outstanding | 4.29 | |||||
| Days Payable | 59.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -82.29 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 14.81 | |||||
| Operating Margin % | -129.83 | |||||
| Net Margin % | -162.58 | |||||
| FCF Margin % | -175.96 | |||||
| ROE % | -114.51 | |||||
| ROA % | -49.96 | |||||
| ROIC % | -54.32 | |||||
| ROC (Joel Greenblatt) % | -376.63 | |||||
| ROCE % | -67.01 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.23 | |||||
| PB Ratio | 0.33 | |||||
| Price-to-Tangible-Book | 0.78 | |||||
| EV-to-EBIT | -1.62 | |||||
| EV-to-Forward-EBIT | -1.87 | |||||
| EV-to-EBITDA | -1.62 | |||||
| EV-to-Forward-EBITDA | -1.87 | |||||
| EV-to-Revenue | 2.06 | |||||
| EV-to-Forward-Revenue | 1.56 | |||||
| EV-to-FCF | -1.16 | |||||
| Earnings Yield (Greenblatt) % | -61.73 | |||||
| FCF Yield % | -129.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xbrane Biopharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 20.854 | ||
| EPS (TTM) (€) | -0.134 | ||
| Beta | 1.3 | ||
| Volatility % | 194.38 | ||
| 14-Day RSI | 38.64 | ||
| 14-Day ATR (€) | 0.005323 | ||
| 20-Day SMA (€) | 0.026805 | ||
| 12-1 Month Momentum % | -97.23 | ||
| 52-Week Range (€) | 0.012509 - 1.024642 | ||
| Shares Outstanding (Mil) | 1,529.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xbrane Biopharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xbrane Biopharma AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xbrane Biopharma AB Frequently Asked Questions
What is Xbrane Biopharma AB(STU:7XB)'s stock price today?
The current price of STU:7XB is €0.02. The 52 week high of STU:7XB is €1.02 and 52 week low is €0.01.
When is next earnings date of Xbrane Biopharma AB(STU:7XB)?
The next earnings date of Xbrane Biopharma AB(STU:7XB) is 2024-05-16.
Does Xbrane Biopharma AB(STU:7XB) pay dividends? If so, how much?
Xbrane Biopharma AB(STU:7XB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers